Novartis has signed a development and licensing agreement with Indian biopharmaceutical company Biological E Limited (BioE) to deliver two vaccines that protect against typhoid and paratyphoid fevers.
Under terms of the agreement, pharmaceutical company Novartis will transfer technology to BioE, which will be responsible for the manufacture, further clinical development, approval and distribution of the vaccines in the developing world.
Novartis will retain patent rights to the vaccines in developed countries.
Two patents will be transferred from Novartis to BioE in the deal. The first covers a monovalent typhoid vaccine, and the second covers a vaccine, still in development, which protects against both typhoid and paratyphoid fevers. Rights to the dual-action vaccine will be transferred after a proof of concept has been completed to improve its safety and immunogenicity – the ability to provoke an immune response.
Don Ganem, vice president and global head of infectious diseases at the Novartis Institutes for BioMedical Research, said: “BioE has a proven track record in vaccine manufacture, and capabilities to clinically develop and deliver WHO [World Health Organisation] pre-qualified affordable vaccines to the developing world. We are pleased to be working with them to address this unmet need.”
Ted Bianco, director of technology transfer and acting director of the Wellcome Trust, which is supporting the development of the dual-action vaccine, said: “Typhoid and paratyphoid are major causes of life-threatening disease worldwide and with the emergence of resistance to all of the commonly used antibiotics, they are becoming increasingly difficult to treat.”
“This licensing deal takes us a step closer to getting much-needed affordable vaccines into the communities that need them most,” he added.
According to the WHO, around 22 million cases of typhoid fever are reported worldwide every year, and a statement on Novartis’s website says there are 5 million annual cases of paratyphoid A fever, one type of the disease. Typhoid and paratyphoid are more prevalent in areas without adequate sanitation and access to clean water.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Novartis, Biological E Limited, vaccines, typhoid, developing and licensing agreement
